{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:39:59Z","timestamp":1753882799509,"version":"3.41.2"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p> Tumor necrosis factor-\u03b1 antagonists have become a therapeutic mainstay for various inflammatory diseases including Hidradenitis Suppurativa. Despite their clinical efficacy, these medications have been associated with the rare development of demyelinating diseases. We report a 29-year-old male who developed neurological symptoms while taking adalimumab, a tumor necrosis factor-\u03b1 antagonist, for treatment of Hidradenitis Suppurativa. The patient was subsequently diagnosed with radiologically isolated syndrome based on magnetic resonance imaging findings. The exact temporal relationship between demyelinating disease and tumor necrosis factor-\u03b1 antagonists is poorly understood. Also, there remain a few effective treatment options for severe inflammatory diseases like Hidradenitis Suppurativa. In cases where a patient exhibits clinical stability and structural resolution following the development of neurological symptoms after tumor necrosis factor-\u03b1 antagonist therapy, and there is a lack of other effective treatments to control extensive inflammatory disease, restarting the tumor necrosis factor-\u03b1 antagonist could be considered provided there is neurology approval and close monitoring. <\/jats:p>","DOI":"10.1177\/2050313x211003057","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T09:18:00Z","timestamp":1615972680000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["A case report about adalimumab-induced radiologically isolated syndrome: A significant side effect of tumour necrosis factor inhibitors"],"prefix":"10.1177","volume":"9","author":[{"given":"Joshua","family":"Onasanya","sequence":"first","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9e A","family":"Beach","sequence":"additional","affiliation":[{"name":"Women\u2019s College Hospital, Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"bibr1-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-33101-8_3"},{"key":"bibr2-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"bibr3-2050313X211003057","unstructured":"AbbVie\u2019s HUMIRA\u00ae (Adalimumab) Receives First and Only Health Canada approval for moderate to severe Hidradenitis Suppurativa, https:\/\/www.newswire.ca\/news-releases\/abbvies-humira-adalimumab-receives-first-and-only-health-canada-approval-for-moderate-to-severe-hidradenitis-suppurativa-564353901.html (accessed 15 October 2020)."},{"issue":"18","key":"bibr4-2050313X211003057","first-page":"2385","volume-title":"Drugs","volume":"72","author":"Burness CB","year":"2012"},{"key":"bibr5-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1755008."},{"key":"bibr6-2050313X211003057","unstructured":"Ustekinumab product monograph, https:\/\/www.janssen.com\/canada\/sites\/www_janssen_com_canada\/files\/prod_files\/live\/stelara_cpm.pdf (accessed 9 January 2021)."},{"key":"bibr7-2050313X211003057","unstructured":"2018 HUMIRA\u00ae (adalimumab) injection, for subcutaneous use\u2014FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf (accessed 1 September 2020)."},{"key":"bibr8-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2113-2"},{"issue":"1","key":"bibr9-2050313X211003057","first-page":"239","volume":"34","author":"Bensouda-Grimaldi L","year":"2007","journal-title":"J Rheumatol"},{"key":"bibr10-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2625-8"},{"key":"bibr11-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcr237"},{"key":"bibr12-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419895155"},{"key":"bibr13-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2419-8"},{"key":"bibr14-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1423131"},{"key":"bibr15-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0055-1"},{"issue":"9","key":"bibr16-2050313X211003057","first-page":"1542","volume":"41","author":"Hosseiny M","year":"2020","journal-title":"Am J Neuroradiol"},{"key":"bibr17-2050313X211003057","unstructured":"Radiologically Isolated Syndrome (RIS). https:\/\/www.cedars-sinai.org\/health-library\/diseases-and-conditions\/r\/radiologically-isolated-syndrome-ris.html (accessed 15 November 2020)."},{"key":"bibr18-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6"},{"key":"bibr19-2050313X211003057","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0742-1"},{"issue":"5","key":"bibr20-2050313X211003057","first-page":"1027","volume":"33","author":"Toussirot E","year":"2006","journal-title":"J Rheumatol"}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X211003057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X211003057","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X211003057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T19:54:49Z","timestamp":1740945289000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X211003057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":20,"alternative-id":["10.1177\/2050313X211003057"],"URL":"https:\/\/doi.org\/10.1177\/2050313x211003057","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"type":"print","value":"2050-313X"},{"type":"electronic","value":"2050-313X"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"2050313X211003057"}}